| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 442,497 | - |
| Cost of revenue (excluding amortization and depreciation) | 35,149 | - |
| Research and development expense (reversal) recognized-Solriamfetol | 32,094 | - |
| Research and development expense (reversal) recognized-AXS-05 | 42,896 | - |
| Research and development expense (reversal) recognized-AXS-07 | 15,379 | - |
| Research and development expense (reversal) recognized-AXS-12 | 6,019 | - |
| Research and development expense (reversal) recognized-AXS-14 | 5,951 | - |
| Other research and development | 11,942 | - |
| General and administrative expense (excluding share-based compensation expense) | 44,623 | - |
| Selling and marketing expense (excluding share-based compensation expense) | 305,864 | - |
| Stock-based compensation expense | 71,022 | - |
| Loss in fair value of contingent consideration | 6,595 | - |
| Interest expense, net | -5,385 | - |
| Other segment items | 14,193 | - |
| Profit Loss | -154,615 | - |
| Adjustments and reconciling items | 0 | - |
| Net loss | -154,615 | -107,386 |
| Stock-based compensation expense | 71,022 | 47,919 |
| Amortization of intangible asset | 4,768 | 3,161 |
| Amortization of debt discount | 1,142 | 984 |
| Loss on debt extinguishment | -10,385 | -10,385 |
| Depreciation | 389 | 269 |
| Loss in fair value of contingent consideration | 6,595 | -6,590 |
| Gain from lease modification | 2,250 | 2,250 |
| Non-cash lease expense | 2,249 | 1,432 |
| Right-of-use asset amortization for finance lease | 1,633 | 949 |
| Change in operating lease liability | -373 | -191 |
| Accounts receivable, net | 54,506 | 56,824 |
| Inventories, net | 7,020 | 2,026 |
| Prepaid expenses and other current assets | 7,811 | 4,360 |
| Non-current inventory and other assets | 5,159 | 3,223 |
| Accounts payable | -17,770 | 19,631 |
| Accrued expenses and other current liabilities | 76,569 | 22,322 |
| Net cash used in operating activities | -74,752 | -75,798 |
| Purchases of equipment | 409 | 351 |
| Net cash used in investing activities | -409 | -351 |
| Proceeds from draw down of debt | 260,000 | 190,000 |
| Payment of debt issuance costs | 3,638 | 3,638 |
| Repayment of debt | 261,988 | 191,988 |
| Payments on principal portion of finance lease obligation | 1,583 | 919 |
| Proceeds from issuance of common stock upon financing | 62,229 | 52,283 |
| Cash paid for common stock issuance costs | 1,099 | 910 |
| Proceeds from issuance of common stock upon exercise of options and under employee stock purchase plan | 44,220 | 28,696 |
| Payment of contingent consideration | -6,995 | -4,488 |
| Payments of tax withholdings on stock awards | 6,066 | 5,224 |
| Net cash provided by financing activities | 85,080 | 63,812 |
| Net increase (decrease) in cash | 9,919 | -12,337 |
| Cash and cash equivalents at beginning of period | 315,353 | - |
| Cash and cash equivalents at end of period | 325,272 | - |
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)